Lack of elevation of serum S100B in patients with metastatic melanoma as a predictor of outcome after induction with an autologous vaccine of proliferating tumor cells and dendritic cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 23, Issue 2, 2008, Pages 214-221

  Schiltz, Patric M ^a   Dillman, Robert O ^a   Korse, Catharina M ^b   Cubellis, James M ^a   Lee, Gregory J ^a   De Gast, Gijsbert C ^b  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Dendritic cells; LDH; Melanoma; S100B; Tumor markers; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CELL ANTIGEN; CORTICOSTEROID DERIVATIVE; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; PROTEIN S100B; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MELANOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEROLOGY; TREATMENT OUTCOME;

CANCER VACCINES; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; HYDRO-LYASES; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NERVE GROWTH FACTORS; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 43049103102     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.2007.0432     Document Type: Article

References (25)

1. Dillman RO, Nayak SK, Barth NM, et al. Clinical experience with autologous tumor cell lines for patientspecific vaccine therapy in metastatic melanoma. Cancer Biother Radiopharm 1998;13:165.
2. Dillman RO, DeLeon C, Beutel LD, et al. Short-term autologous tumor cell lines for the active specific immunotherapy of patients with metastatic melanoma. Crit Rev Oncol Hematol 2001;39:115.
3. Dillman RO, DePriest C, DeLeon C, et al. Patient-specific vaccines derived from autologous tumor cell lines as active specific immunotherapy: Results of exploratory phase I/II trials in patients with metastatic melanoma. Cancer Biother Radiopharm 2007;21:309.
4. Dillman RO, Selvan S, Schiltz P, et al. Phase I/II trial of melanoma patient-specific vaccine of proliferating autologous tumor cells, dendritic cells, and GM-CSF: Planned interim analysis. Cancer Biother Radiopharm 2004;5:658.
5. Dillman RO, Selvan SR, Schiltz PM. Patient-specific dendritic-cell vaccines for metastatic melanoma. N Engl J Med 2006;355:1179.
6. Finck SJ, Giulliano AE, Morton D. LDH and melanoma. Cancer 1983;51:840.
7. Deichmann M, Benner A, Bock M, et al. S100-beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891.
8. Torabian S, Kashani-Sabet M. Biomarkers for melanoma. Curr Opin Oncol 2005;17:167.
9. Linette GP, Carlson JA, Slominski A, et al. Biomarkers in melanoma: Stage III and IV disease. Expert Rev Mol Diagn 2005;5:65.
10. Nakajima T, Watanabe S, Sato Y, et al. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus and its diagnostic application. Cancer 1982;50:912.
11. Gaynor R, Herschman HR, Irie R, et al. S100 protein: A marker for human malignant melanomas: Lancet 1981;1:869.
12. Bonfrer JM, Korse CM, Nieweg OE, et al. The luminescence immunoassay S-100: A sensitive test to measure circulating S100B: Its prognostic value in metastatic melanoma. Br J Cancer 1998;77:2210.
13. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. Clin Biochem 2004;37:512.
14. Markowitz J, Mackerelol AD, Jr, Carrier F, et al. Design of inhibitors for S100B. Curr Top Med Chem 2005;5:1093.
15. Curry BJ, Farrelly M, Hersey P. Evaluation of S100 beta assays for the prediction of recurrence and prognosis in patients with AJCC stages I-III melanoma. Melanoma Res 1999;9:557.
16. Hauschild A, Engel G, Brenner W, et al. S100B protein detection in serum is a significant prognostic factor in metastatic melanoma. Oncology 1999;56:338.
17. Andres R, Mayordomo JI, Zaballos P, et al. Prognostic value of serum S100B in malignant melanoma. Tumori 2004;90:607.
18. Henze G, Dummer R, Joller-Jemelka HI, et al. Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatol 1997;194:208.
19. Hamberg AP, Korse CM, Bonfrer JMG, et al. Serum S100B is suitable for prediction and monitoring of response to chemoimmunotherapy in metastatic malignant melanoma. Melanoma Res 2003;13:45.
20. Smith LH, Korse CM, Hart AA, et al. Normal values of serum S100B predict prolonged survival for stage IV melanoma patients. Eur J Cancer 2005;41:386.
21. Jury CS, Mcallister EJ, Mackie RM. Rising levels of serum S100 protein precede other evidence of disease progression in patients with malignant melanoma. Br J Dermatol 2000;143:269.
22. Guo HB, Stoffel-Wagner B, Bierwirth T, et al. Clinical significance of serum S100 in metastatic melanoma. Cancer 1995;31A:924.
23. Hauschild A, Engel B, Brenner W, et al. Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or immunotherapy. Br J Dermatol 1999;140:1065.
24. Hauschild A, Michaelson J, Brenner W et al. Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999;9:155.
25. Bonfalvi T, Udvarhelyi N, Orosz Z, et al. Heterogenous S100B protein expression patterns in malignant melanoma and association with serum protein levels. Oncology 2003;64:374.